Onconetix, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Onconetix, Inc. Onconetix, Inc. (Nasdaq: ONCO) is a commercial-stage biotechnology company focused on the research, development, and commercialization of proprietary therapeutics, diagnostics, and services for men's health and oncology. The company offers Entadfi, an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a prostate disorder; Proclarix, an advanced in vitro protein-based blood diagnostic test approved for sale in the European Union under the In Vitro Diagnostic Regulation for screening and diagnosis of prostate cancer in men with indeterminate prostate-specific antigen levels, which utilizes the same blood sample as standard PSA tests; and associated clinician services through its pipeline in oncology therapeutics and diagnostics. Founded in 2018 and headquartered in Cincinnati, Ohio, Onconetix operates primarily in the United States and European Union, with its wholly owned subsidiary Proteomedix AG supporting diagnostic commercialization and a license agreement with Labcorp for Proclarix development and distribution. Recent developments include the September 2025 licensing by Proteomedix of manufacturing intellectual property to Immunovia AB for pancreatic cancer diagnostics reagents; a July 2025 definitive merger agreement with Ocuvex Therapeutics, Inc. to acquire its ophthalmic assets including the FDA-approved Omlonti for ocular hypertension and glaucoma, expected to close in Q4 2025 pending approvals; an April 2025 non-binding letter of intent preceding the Ocuvex merger; a name change from Blue Water Biotech, Inc.; and October 2024 financing via a $2.0 million private placement of Series C preferred stock and warrants plus a $25 million equity line of credit.
Realbotix Reports Financial Results for Q2-2026
Onconetix, Inc. Announces 1-for-10 Reverse Stock Split
Realbotix Provides Update on Nasdaq Listing
Realbotix Provides Update on Nasdaq Listing
Onconetix (ONCO) Stock Surges Over 23% Overnight: Why Is It Moving?
Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study
Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study
Onconetix Highlights Realbotix's Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to Ericsson
Onconetix Highlights Realbotix AI Humanoid Robot Delivery Update
Onconetix Appoints David White as Chief Executive Officer and Sammy Dorf as Member of the Board of Directors
What's Going On With Onconetix Shares On Friday?
Onconetix Highlights Realbotix's Role in Ericsson's World-First 6G Trial Demonstration
Onconetix, Inc. Announces 1-for-5 Reverse Stock Split
Onconetix, Inc. (NASDAQ:ONCO) Short Interest Down 13.9% in January
Onconetix, Inc. (ONCO) M&A Call Transcript
Realbotix Corp. Announces the Sale of Realbotix, LLC Subsidiary to a NASDAQ Listed Issuer
Onconetix to Acquire Realbotix LLC, USA-based, AI-Powered Humanoid Robotics Company
Contrasting AstraZeneca (NASDAQ:AZN) and Onconetix (NASDAQ:ONCO)
Onco-Innovations Chairs Colorectal Cancer Canada Precision Oncology Forum Generating Roadmaps for the Next Era of Cancer Care
Onco-Innovations Engages Investment Bank to Pursue Nasdaq Cross-listing and Potential Concurrent Equity Offering